APTOSE BIOSCIENCES INC(TSX:APS) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to APS. APS was compared to 23 industry peers in the Biotechnology industry. APS may be in some trouble as it scores bad on both profitability and health. APS is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year APS has reported negative net income.

In the past year APS has reported a negative cash flow from operations.

APS had negative earnings in each of the past 5 years.

In the past 5 years APS always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of APS (-327.57%) is worse than 62.50% of its industry peers.

		Industry Rank	Sector Rank
ROA	-327.57%
ROE	N/A
ROIC	N/A

ROA(3y)-185.13%

ROA(5y)-125.06%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

APS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, APS has more shares outstanding

The number of shares outstanding for APS has been increased compared to 5 years ago.

APS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

APS has an Altman-Z score of -79.77. This is a bad value and indicates that APS is not financially healthy and even has some risk of bankruptcy.

APS has a worse Altman-Z score (-79.77) than 62.50% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-79.77

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 1.05 indicates that APS should not have too much problems paying its short term obligations.

Looking at the Current ratio, with a value of 1.05, APS is in the better half of the industry, outperforming 62.50% of the companies in the same industry.

APS has a Quick Ratio of 1.05. This is a normal value and indicates that APS is financially healthy and should not expect problems in meeting its short term obligations.

APS has a Quick ratio of 1.05. This is in the better half of the industry: APS outperforms 62.50% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.05
Quick Ratio	1.05

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for APS have decreased strongly by -230.01% in the last year.

EPS 1Y (TTM)-230.01%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-530.68%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 18.54% on average over the next years. This is quite good.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y76.35%

EPS Next 2Y30.79%

EPS Next 3Y20.94%

EPS Next 5Y18.54%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for APS. In the last year negative earnings were reported.

Also next year APS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

APS's earnings are expected to grow with 20.94% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y30.79%

EPS Next 3Y20.94%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

APS does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

APTOSE BIOSCIENCES INC

TSX:APS (3/7/2025, 7:00:00 PM)

4.52

+0.19 (+4.39%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-08 2024-11-08/amc

Earnings (Next)03-24 2025-03-24/amc

Inst Owners6.66%

Inst Owner ChangeN/A

Ins Owners1.13%

Ins Owner ChangeN/A

Market Cap9.67M

Analysts82.86

Price Target167.29 (3601.11%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)66.9%

Min EPS beat(2)64.27%

Max EPS beat(2)69.52%

EPS beat(4)4

Avg EPS beat(4)37.14%

Min EPS beat(4)3.29%

Max EPS beat(4)69.52%

EPS beat(8)6

Avg EPS beat(8)16.25%

EPS beat(12)9

Avg EPS beat(12)9.71%

EPS beat(16)12

Avg EPS beat(16)10.05%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)2727.12%

PT rev (3m)2886.66%

EPS NQ rev (1m)-2900%

EPS NQ rev (3m)-767.77%

EPS NY rev (1m)0%

EPS NY rev (3m)58.56%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-37.52

EYN/A

EPS(NY)-3.2

Fwd EYN/A

FCF(TTM)-24.91

FCFYN/A

OCF(TTM)-24.91

OCFYN/A

SpS0

BVpS-6.12

TBVpS-6.12

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-327.57%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-185.13%

ROA(5y)-125.06%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score2

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.05
Quick Ratio	1.05
Altman-Z	-79.77

F-Score2

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)64.76%

Cap/Depr(5y)62.67%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-230.01%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-530.68%

EPS Next Y76.35%

EPS Next 2Y30.79%

EPS Next 3Y20.94%

EPS Next 5Y18.54%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y28.51%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year41.1%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y6.48%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y6.39%

OCF growth 3YN/A

OCF growth 5YN/A

APTOSE BIOSCIENCES INC (APS.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens